hydroxychloroquine plus macrolides - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical worsening 0.30 [0.22, 0.41]< 10%1 study (- / 1)100.0 %criticalnot evaluable very lowcrucial-
deaths 1.07 [0.69, 1.66]< 162%4 studies (- / 4)38.4 %criticalnot evaluable very lowcrucial-
deaths (time to event analysis only) 1.35 [1.05, 1.74]< 10%3 studies (- / 3)0.9 %criticalnot evaluable very lowcrucial-
hospitalization 0.38 [0.27, 0.54]< 10%1 study (- / 1)100.0 %criticalnot evaluable very lowimportant-
ventilation (time to event analysis only) 0.43 [0.16, 1.14]< 10%1 study (- / 1)95.5 %seriousnot evaluable lowimportant-
cardiac arrest 2.13 [1.12, 4.05]< 10%1 study (- / 1)1.1 %seriousnot evaluable lowimportant-
abnormal ECG findings 1.55 [0.89, 2.68]< 10%1 study (- / 1)5.9 %seriousnot evaluable lownon important-
arrhythmia 2.21 [1.38, 3.52]< 10%1 study (- / 1)0.0 %seriousnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 95, 94